Fraunhofer-Gesellschaft

Publica

Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

A phase 2b study evaluating the efficacy and safety of subcutaneously administered tregalizumab in subjects with active Rheumatoid Arthritis (RA) despite treatment with Methotrexate (MTX)

 
: Vollenhoven, R.F. van; Keystone, E.C.; Strand, V.; Pacheco-Tena, C.; Vencovsky, J.; Behrens, F.; Zipp, D.; Rharbaoui, F.; Wolter, R.; Tiemann, R.-D.; Knierim, L.; Schmeidl, R.; Zhou, X.; Aigner, S.; Daelken, B.; Wartenberg-Demand, A.

Arthritis & rheumatology 67 (2015), Supplement S10, Abstract 972
ISSN: 2326-5191
ISSN: 2326-5205
American College of Rheumatology/Association of Reproductive Health Professionals (ACR/ARHP Annual Meeting) <2015, San Francisco/Calif.>
English
Abstract
Fraunhofer IME ()

Abstract
Background/Purpose:
In autoimmune diseases reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed (1). Tregalizumab (BT-061) is a humanized, anti-CD4 mAb, inducing selective Treg activation in vitro. Previous trials suggested efficacy in RA at doses ≥25 mg subcutaneously (SC). In a population PK/PD analysis, down-modulation of CD4 expression was identified as a biomarker to monitor CD4 target engagement in humans.
Methods:
This two-part, Phase 2b randomized controlled trial (RCT) included subjects with active RA for ≥6 months despite MTX (≥15mg/wk), with ≥6/28 TJC, ≥6/28 SJC and elevated CRP or ESR. Subjects were randomized to receive 25 mg, 100 mg, 200 mg, or PBO once-weekly SC injection + MTX over 24 wks. Primary endpoint was ACR20 at wk 12. At wk 12 (end of Main part I), non-responders were re-randomized to active treatment or higher doses. Subjects responding at wk 24 (end of Main part II) could extend treatment for an additional 24 wks. A data safety monitoring board (DSMB) was established for safety evaluation throughout the study.
Results:
Of 321 subjects enrolled from Europe, USA, Canada, Russia and Mexico, 37 (11.5%) withdrew at ≤ wk 12. Demographics and baseline disease characteristics were well balanced across groups: mean SJC and TJC 16 and 24, respectively; CRP 11.7 mg/L, DAS (ESR) 6.58 and HAQ-DI 1.56. ACR20 responders at wk 12 (42.3%/47%/44.3% vs. 35.2% in 25 mg, 100 mg, 200 mg groups and PBO, respectively), ACR20 responders at wk 24 and secondary endpoints did not differ significantly between tregalizumab groups and PBO. However, dose dependent modulation of CD4 expression on T cells occurred rapidly with BT-061 treatment, as predicted from previous analyses. Through wk 12, TEAE (39.4% and 37.5%) and serious TEAEs rates (2.1% and 1.3%) were similar between BT-061 and PBO. For responder at wk 24, TEAEs (48.3% and 52.3%) were similar between BT-061 and PBO. Serious TEAEs were only reported in BT-061 treated subjects (2%). Three deaths occurred considered unrelated to treatment (car accident, acute coronary syndrome, death of unknown cause in a war area). There was no difference in infections between tregalizumab and PBO. One serious infection (peritonitis) occurred at wk 22 in the 25 mg dose group. Apart from acute coronary syndrome with fatal outcome, no further MACE events, Tuberculosis, opportunistic infections nor malignancies were reported.
Conclusion:
No tested doses of tregalizumab demonstrated significant efficacy improving signs and symptoms of active RA based on ACR20 responses at wk 12 and 24 despite dose dependent down-modulation of CD4 expression. Tregalizumab was generally well tolerated.

: http://publica.fraunhofer.de/documents/N-404591.html